Table 2 Cost effectiveness analysis
From: Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
Strategy | Cost,US$ (IC95%) | Diff ($) | QUALYs (IC95%) | Diff (QALYs) | NMB(US$ (IC95%) |
|---|---|---|---|---|---|
Podotimod | 797 (794–801) | 0,95 (0,94–0,95) | 4121 (4114–4127) | ||
Placebo | 1175(1169–1181) | 378 | 0,94 (0,94.9,94) | 0,01 | 3710 (3700–3720) |